Introduction {#sec1-1}
============

Cervical cancer (CC) is the second most common cancer among Malaysian women, and was the fifth most common cause of cancer death in 2012 (Ferlay et al., 2013). Human papillomavirus (HPV) is the necessary cause of CC (Walboomers et al., 1999), most commonly associated with HPV-16/18. CC has a substantial economic burden in Malaysia, with an estimated direct medical cost of 39.2 million Malaysian Ringgits (MYR) and a further MYR 12.4 million in indirect costs due to productivity lost in 2008 (Aljunid et al., 2010).

Papanicolaou (Pap) tests for CC screening have been available in Malaysia since the 1960s, and have been free-of-charge since 1995. However, a study by Abdullah et al. (2011) found that \<40% of Malaysian women reported ever having had a Pap test. In 2010, the Malaysian government implemented free HPV vaccination to all 13-year-old girls (Bruni et al., 2015; One Malaysia Community, 2009). Two vaccines are currently available: AS04-adjuvanted HPV-16/18 vaccine (*Cervarix*, GSK; AS04-HPV-16/18v) (Appendix A.1) which protects against HPV-16 and -18, and HPV-6/11/16/18 vaccine (*Gardasil*, Merck and Co., Inc.; 4vHPVv) which in addition protects against HPV-6 and -11 associated with genital warts (GW) (Ghittoni et al., 2015).

Randomised trials comparing AS04-HPV-16/18v and 4vHPVv have reported a superior immune response with AS04-HPV-16/18v (two/three doses) than with 4vHPVv (three doses) (Einstein et al., 2014; Leung et al., 2015).

Originally, three vaccine doses were recommended. However, the World Health Organization recommends a two-dose HPV vaccine schedule in children up to 13-years (4vHPVv) or 14-years (AS04-HPV-16/18v) (World Health Organization (WHO), 2014). Though both vaccines have shown protection against non-vaccine HPV types, current data indicates this may be stronger and broader with AS04-HPV-16/18v than 4vHPVv (Brown et al., 2009; Paavonen et al., 2009; Tjalma et al., 2009). To date, immunogenicity against non-vaccine types has been sustained for up to 9.4 years (Moscicki et al., 2015).

Three HPV cost-effectiveness analyses have been published comparing both vaccines (Aljunid et al., 2010; Ezat and Aljunid, 2010) and two- and three-dose schedules (Aljunid et al., 2013).

The aim of this study is to evaluate the epidemiological and economic consequences of universal mass vaccination (UMV) with two doses of AS04-HPV-16/18v or 4vHPVv in addition to the current CC screening programme in Malaysia, taking into account protection against non-vaccine types.

Materials and Methods {#sec1-2}
=====================

Analyses were conducted from the perspective of the Malaysian Ministry of Health, including only direct medical costs.

A published Markov cohort model was adapted to assess the lifetime effects of AS04-HPV-16/18v or 4vHPVv on cases, deaths, costs, life years, and quality-adjusted life years (QALYs) due to CC and its precursors, and GW (Demarteau and Standaert, 2010).

This model type was considered appropriate to meet the study objective as it adequately reproduces the long natural history of HPV. The model consists of a series of health states through which subjects move, reflecting the progression of low-risk HPV infection to GW and cervical intraepithelial neoplasia (CIN) grade 1, and of oncogenic HPV infection to CIN1, CIN2/3 and invasive CC (Demarteau and Standaert, 2010). The model has 95 one-year cycles.

Malaysian data were used where available, or were supplemented by data from another (Asian) country. CC clinical experts reviewed and validated data inputs and assumptions used in the model (Appendix A.2).

Cohort size was 259,000 13-year-old girls (Department of Statistics Malaysia, 2015a). Age-specific female mortality rates from 2013 were used as background mortality in the model (Appendix Table B.1).

HPV incidence in Malaysian women was calculated from data reported by the HPV information centre (Bruni et al., 2015) (Appendix Table B.2).

As Malaysian data on GW incidence could not be identified, data from Japan were used (Kumamoto et al., 2004) (Appendix Table B.3), and approved by the experts consulted. Appendix Table C.1 lists the yearly transition probabilities used to determine how subjects move between health states in the absence of HPV vaccination.

In 2013, a HPV immunisation coverage of 94% was reported (MoH Malaysia, 2014). Two-dose schedules for both vaccines have been approved in Malaysia. The base-case assumed 100% vaccination coverage with two doses (National Pharmaceutical Control Bureau (NPCB) and MoH Malaysia, 2016).

AS04-HPV-16/18v and 4vHPVv efficacy were sourced from randomised controlled trials (Appendix C.2). As vaccination was considered before sexual activity (age 13), data from women HPV-naïve at study entry were used. Protection against non-vaccine HPV types for both vaccines was considered.

Vaccine effectiveness depends on vaccine efficacy against each HPV type. Efficacy for both vaccines against all endpoints related to vaccine-type HPV (HPV types 6/11/16/18) were assumed equal at 98% (Paavonen et al., 2009; The FUTURE II Study Group, 2007) (Appendix Table C.3). Protective efficacy against grouped non-vaccine types were differentiated per vaccine based on the reported clinical trial values (Appendix C.4). HPV type distributions in CIN2/3 and CC were specific for Malaysia, data for CIN1 were from South-Eastern Asia, as insufficient data for Malaysia were available (Bruni et al., 2015). HPV type distribution for GW was based on expert opinion.

Overall vaccine effectiveness was estimated based on vaccine-type and non-vaccine-type efficacies and HPV type distribution for each lesion type and calculated for each model cycle to allow for less than lifetime vaccine protection. The base-case analysis assumed life-long efficacy related to vaccine-type and non-vaccine-type HPV.

In Malaysia, 20--65-year-old women are recommended to undergo Pap testing every 3 years (MoH Malaysia and Academy of Medicine, 2003). However, the experts felt that the reported screening coverage of 59.7% within 3 years (Abdullah et al., 2011) probably represented women who had ever had a Pap smear. Similarly, Gakidou et al., (2008) found that, in 2002, 46.8% of women reported never having had a pelvic examination. Overall, they estimated an effective 3-year screening coverage of 30.5%. However, this did not reflect the number of women who underwent CC screening every 3 years. Therefore, it was assumed that 29.9% would have a Pap test at 30-years and 29.9% at 45-years. The detection rates of CIN1 and CIN2/3 were 0.580 and 0.610, respectively (Appendix Table C.1). It was estimated that 5.5% of Pap tests would be positive (Bergeron et al., 2005; Fender et al., 2003).

Only direct medical costs were included due to a lack of data on other costs. The same price per dose was used for both vaccines.

Costs of regular screening and treatment were derived from: (1) resource use from a previous publication by Aljunid et al. (2010) and (2) unit costs retrieved from the 2010 accounting database of two Malaysian public hospitals (Appendix C.1b). Costs retrieved represented 2012 costs and were updated to 2015 values using the relative price index for health components from 2012 to August 2015, resulting in a 10% increase (Department of Statistics Malaysia, 2015b, c).

Regular screening costs for subjects with negative or false-positive Pap tests were MYR 30 or 1,190, respectively (Aljunid et al., 2016). Annual treatment costs for GW, CIN1, CIN2/3 and CC were MYR 1,834, 2,102, 2,461, and 62,537, respectively. It was assumed that no CIN1-detected patients would undergo treatment (MoH Malaysia and Academy of Medicine, 2003) but that there would be additional follow-up costs. It was assumed that all CIN2/3-detected patients would undergo treatment (Expert opinion; Appendix Table C.1).

Yearly disutilities for precancerous/cancerous states published in HPV cost-effectiveness analyses were used (Appendix C.5). The model runs in yearly cycles using disutility values for a single year, equalling the proportion of a single QALY lost if the disease occurs within that year. All conditions except CC, CC death, all-cause mortality and CC survival are modelled to occur over a single year. The disutility for CC is applied over the number of years the health state is modelled to last. In the current analysis, the average retention in the CC health state is 2.25 years. For CC survival, the disutility is applied over the remaining lifetime of the subject. Disutilities were subtracted from a baseline utility of 1 across all ages for every year in the model. No decrements were assumed by age for non-diseased subjects.

Model outcomes included: CIN1, CIN2/3, CC, deaths due to CC, GW, costs, life years, and QALYs. Incremental cost-effectiveness ratios (ICERs) were computed. Results were presented as undiscounted values (for all outcomes) and discounted values (for cost, QALYs, life years, and ICERs).

As per Malaysian guidelines, health and cost outcomes were discounted at 3% per annum (ISPOR, 2015).

One-way sensitivity analyses were performed to evaluate robustness of the results for changes in selected model variables. Ninety-five% confidence intervals (CIs) were used for vaccine efficacy related to protection against non-vaccine types (Appendix Table D.1). Other inputs were varied ±20% of the base-case values, except for the discount rate, which varied from 1.5-5%. A specific analysis was added to assess the impact of using an unadjusted distribution for HPV-16/18.

A probabilistic sensitivity analysis (PSA) was performed to assess parameter uncertainty in the model. Ten thousand replicates were generated (Appendix Table D.2).

A separate scenario assessed the impact of a lower (39.7%) 5-year survival rate for CC (Razak et al., 2013) instead of 57.2% used in the base-case.

A two-way sensitivity analysis was performed to assess the impact of the longevity of cross-protection for both vaccines. The duration of protection varied from 5-100 years with 5-year increments for both vaccines. Cost and QALY were calculated for each of the values and tabulated (Appendix E).

Results {#sec1-3}
=======

Model validation {#sec2-1}
----------------

The model adequately reproduced age-dependent CC incidence, CC mortality in Malaysia and GW incidence in Japan in 2002 (Ferlay et al., 2013; Kumamoto et al., 2004) (Appendix Figure C.6, C.7 and C.8).

Health and economic impacts {#sec2-2}
---------------------------

In the base-case, AS04-HPV-16/18v prevented no cases of GW whereas 4vHPVv prevented 4,241 GW cases, but AS04-HPV-16/18v resulted in 361 fewer CC cases and 115 fewer deaths over the cohort's lifetime versus 4vHPVv ([Table 1](#T1){ref-type="table"}). AS04-HPV-16/18v resulted in CC and CIN cost savings that outweighed 4vHPVv associated with GW cost savings. AS04-HPV-16/18v dominated 4vHPVv with MYR 18.50 million cost savings and 246 QALYs gained.

###### 

Cases Remaining, Total Costs, Life Years and QALYs Gained for Unvaccinated, AS04-HPV-16/18v and 4vHPVv, Incremental Vvalues AS04-HPV-16/18v vs. 4vHPVv

                                                   Base-case: 5-year cervical cancer survival 57.2%   Alternative scenario: 5-year cervical cancer survival 39.7%                                                                                         
  ------------------------------------------------ -------------------------------------------------- ------------------------------------------------------------- ------------- ----------------------------- ------------- ------------- ------------- -----------------------------
  Cases                                                                                                                                                                                                                                                   
   CIN1 screening-detected                         1,008                                              636                                                           555           -81                           1,007         636           555           -81
   Genital warts                                   5,648                                              1,407                                                         5,648         4,241                         5,647         1,407         5,648         4,241
   CIN2/3 screening-detected                       684                                                287                                                           163           -124                          684           287           163           -124
   Cervical cancer                                 2,552                                              885                                                           524           -361                          2,552         885           524           -361
  Cervical cancer deaths                           811                                                280                                                           165           -115                          1,184         412           245           -167
  Undiscounted costs (Malaysian Riggits; MYR)                                                                                                                                                                                                             
   Vaccine                                         0                                                  69,412,000                                                    69,412,000    0                             0             69,412,000    69,412,000    0
   Screening                                       167,163,323                                        169,761,617                                                   169,470,060   -291,557                      167,163,400   169,761,621   169,470,082   -291,539
   Genital warts                                   15,904,119                                         3,963,704                                                     15,904,498    11,940,794                    15,903,788    3,963,687     15,904,401    11,940,714
   CIN1 treatment                                  2,117,541                                          1,335,837                                                     1,166,268     -169,569                      2,117,463     1,335,775     1,166,246     -169,529
   CIN2/3 treatment                                1,684,049                                          706,916                                                       401,733       -305,183                      1,684,049     706,916       401,733       -305,183
   Cervical cancer                                 749,055,510                                        260,059,686                                                   153,985,579   -106,074,107                  963,093,783   333,112,601   196,415,195   -136,697,406
   Total cost differences                          --                                                 --                                                            --            -94,899,622                   --            --            --            -125,522,943
  Undiscounted outcomes                                                                                                                                                                                                                                   
   Life years                                      12,699,197                                         12,702,717                                                    12,703,476    759                           12,696,180    12,701,540    12,702,695    1,155
   Quality-adjusted life years (QALYs)             12,694,333                                         12,701,225                                                    12,702,455    1,230                         12,690,780    12,699,937    12,701,616    1,679
   Incremental cost-effectiveness ratio (ICERs)                                                                                                                                   AS04-HPV-16/18v is dominant                                             AS04-HPV-16/18v is dominant
  Discounted results                                                                                                                                                                                                                                      
   Total costs (Malaysian Riggits; MYR)            272,272,530                                        215,835,194                                                   197,330,893   -18,504,301                   311,889,505   229,685,818   205,593,197   -24,092,621
   Life years                                      6,052,441                                          6,053,275                                                     6,053,455     180                           6,051,657     6,052,970     6,053,253     283
   Quality-adjusted life years (QALYs)             6,051,232                                          6,052,900                                                     6,053,146     246                           6,050,364     6,052,579     6,052,936     357
   Incremental cost-effectiveness ratios (ICERs)                                                                                                                                  AS04-HPV-16/18V is dominant                                             AS04-HPV-16/18v is dominant

CIN, cervical intraepithelial neoplasia; CIN1/2/3, cervical intraepithelial neoplasia grade 1/2/3; HPV, human papillomavirus; AS04-HPV-16/18v, AS04-adjuvanted HPV-16/18 vaccine (*Cervarix*); 4vHPVv, HPV-6/11/16/18 vaccine (*Gardasil*); ICER, incremental cost-effectiveness ratio; MYR, Malaysian Ringgits; QALYs, quality-adjusted life years

Sensitivity analyses {#sec2-3}
--------------------

One-way sensitivity analysis was assessed on discounted cost and QALY separately. The discount rate was the most influential variable for costs ([Figure 1](#F1){ref-type="fig"}) and QALYs closely followed by a change in HPV-16/18 distribution ([Figure 2](#F2){ref-type="fig"}). A discount rate between 1.5-5% did not change the dominance of AS04-HPV-16/18v over 4vHPVv.

![Univariate Sensitivity Analyses on Cost for AS04-HPV-16/18v vs. 4vHPVv. CC, cervical cancer; CIN1, cervical intraepithelial neoplasia grade 1; CIN3, cervical intraepithelial neoplasia grade 3; GW, genital warts; HPV, human papillomavirus; HPVonc, oncogenic human papillomavirus; Pap, Papanicolaou.](APJCP-19-933-g001){#F1}

![Univariate Sensitivity Analyses on QALY for AS04-HPV-16/18v vs. 4vHPVv. CC, cervical cancer; CIN1, cervical intraepithelial neoplasia grade 1; CIN3, cervical intraepithelial neoplasia grade 3; GW, genital warts; HPV, human papillomavirus; HPVonc, oncogenic human papillomavirus; Pap, Papanicolaou; QALY quality-adjusted life year.](APJCP-19-933-g002){#F2}

The PSA results (Appendix Figure D.3) showed AS04-HPV-16/18v was dominant in 96.3% of cases and be dominated in 2.4% of cases.

The 5-year survival rate for CC of 39.7% instead of 57.2% showed more CC deaths (167) were avoided with AS04-HPV-16/18v ([Table 1](#T1){ref-type="table"}). The difference in total discounted cost savings was predicted to increase to MYR 24.09 million, as was the number of QALYs gained (357).

Duration of cross-protection was varied from 5-100 years. AS04-HPV-16/18v was dominant or very cost-effective (i.e., \<1xGDP/capita) in all scenarios tested. CC mortality by Razak et al. (2013) did not change this conclusion. Unadjusted HPV-16/18 distribution in CC resulted in AS04-HPV-16/18v being dominant or cost-effective in 57% of the cases (Appendix E).

Discussion {#sec1-4}
==========

UMV with AS04-HPV-16/18v in 13-year-old Malaysian girls plus CC screening dominated 4vHPVv, with 361 fewer CC cases and 115 fewer deaths, 246 discounted additional QALYs, and MYR 18.5 million saved over the lifetime of the cohort. This was due to the higher reported cross-protection for non-vaccine oncogenic HPV types with AS04-HPV-16/18v (Appendix Table C.3).

4vHPVv prevented 4,241 GW cases vs. AS04-HPV-16/18v. GW are not associated with mortality, so in the current analysis, the benefit of 4vHPVv on GW was outweighed by the benefits of AS04-HPV-16/18v on CC and precancerous lesions.

The model used a two-dose schedule for HPV vaccination. Aljunid et al., (2013) predicted that a two-dose HPV schedule was cost-saving compared with a three-dose schedule. Studies in the United Kingdom and Canada predicted that a two-dose schedule was cost-effective versus screening alone, if protection lasts for ≥10 years, but adding a third dose if protection exceeds ≥20 years (Jit et al., 2015) or \>30 years (Laprise et al., 2014) was not cost-effective.

Two analyses comparing AS04-HPV-16/18v and 4vHPVv reported conflicting results (Aljunid et al., 2010; Ezat and Aljunid, 2010). Ezat and Aljunid (2010) concluded that 4vHPVv had a lower ICER than AS04-HPV-16/18v, due to its efficacy against GW. However, they did not consider the increased protection against non-vaccine types with AS04-HPV-16/18v or present incremental results for both vaccines. Aljunid et al. (2010) evaluated higher protection against non-vaccine types for AS04-HPV-16/18v, and predicted that AS04-HPV-16/18v provided the greatest potential economic benefit (savings of MYR 45.4 million vs. MYR 42.9 million with 4vHPVv).

Analyses comparing AS04-HPV-16/18v and 4vHPVv in other countries also reported conflicting results. Aponte-Gonzalez et al., (2013); Bresse et al., (2013); Brisson et al., (2013); Dee and Howell (2010); Lee et al., (2011); Westra et al. (2013), found more favourable cost-effectiveness with 4vHPVv. Westra et al., (2013) reported a marginal economic difference with 4vHPVv, but better cancer protection with AS04-HPV-16/18v. Jit et al., (2011) (UK) concluded 4vHPVv might reduce healthcare costs and QALYs lost versus AS04-HPV-16/18v, but that AS04-HPV-16/18v might prevent more CC deaths. Capri et al., (2011); Demarteau et al. (2012); Lee et al., (2015) found AS04-HPV-16/18v would provide a better health and economic value than 4vHPVv. In these models, the inputs varied according to country and model used, and Dee and Howell (2010) did not account for the higher non-vaccine HPV type protection with AS04-HPV-16/18v. Notably, models with high discount rates for outcomes and/or high GW rates resulted in better results for 4vHPVv (Bresse et al., 2013; Dee and Howell, 2010; Lee et al., 2015). Westra et al., (2013) investigated the value of protecting against CC alone and against CC and GW, questioning the willingness-to-pay threshold for GW protection.

Both vaccines have different strengths: 4vHPVv protects against GW, but AS04-HPV-16/18v seems to provide greater protection against CC, resulting in cost savings for AS04-HPV-16/18v. Results were largely driven by AS04-HPV-16/18v cross-protection and distribution of HPV types. The base-case assumption was life-long duration for cross-protection. Variation in cross-protection duration did not change the conclusions, but using unadjusted HPV-16/18 distribution had an important effect on the results (Appendix Tables E.7, E.8, E.9).

HPV type varies by country, and AS04-HPV-16/18v protection against non-vaccine HPV types will provide more incremental benefits in countries with a higher prevalence of non-HPV-16/18-related disease. Differences in GW incidence, screening and treatment costs vary between countries impacting the cost-effectiveness of both vaccines.

This study has limitations. Markov cohort models don't account for dynamic effects (e.g., herd protection) or population changes that could have improved the results. This analysis may, therefore, represent a conservative estimate of the benefits of HPV vaccination in Malaysia. Although Malaysian data were used where possible, it was supplemented with regional data when unavailable. Additionally, the nine-valent HPV vaccine was not considered for analysis, which may become available to the Malaysian public in the near future. This should be addressed in a future analysis.

There are no head-to-head vaccine efficacy studies; therefore vaccine effectiveness was estimated based on HPV type distribution and efficacies from individual trials. The model also combined all oncogenic and low-risk HPV types and did not account for the differential progression/regression of each HPV type, which may have favoured protection associated with non-HPV-16/18 types in our analysis, as cancers associated with HPV-16/18 types are reported to burden younger populations more than other HPV types (de Sanjose et al., 2013).

It is unknown whether HPV vaccination will have any long-term effects on type replacement (Drolet et al., 2015). It is also unclear how long protection will last for and whether booster vaccinations will be required. However, long-term follow-up studies for AS04-HPV-16/18v have shown maintained seropositivity for \>9 years (De Vincenzo et al., 2014). Furthermore, Aregay et al. (2013) modelled that AS04-HPV-16/18v antibodies against vaccine-type HPV are expected to last ≥50 years. Kemp et al., (2012) reported persistence of cross-neutralising antibody titres 3 years after AS04-HPV-16/18v vaccination. Similarly, immunogenicity against non-vaccine types was sustained for \>9 years (Moscicki et al., 2015), which strengthens our assumption that protection against non-vaccine types may be long-lasting. A meta-analysis by Malagón et al. (2012) concluded that differences in cross-protection with AS04-HPV-16/18v and 4vHPVv may not be statistically significant nor long-lasting. Taylor et al., (2016) recently summarised that AS04-HPV-16/18v has consistently demonstrated long-lasting (7-9 years), cross-protective efficacy in vaccine recipients, which was also demonstrated in the UK vaccination programme. This strengthens our assumptions on long-lived protection against non-vaccine types with AS04-HPV-16/18v.

We assumed an optimistic, yet reasonable, vaccine coverage of 100%, based on a 94% reported coverage in Malaysia in 2013 (MoH Malaysia, 2014). Changing vaccination coverage in the model would only affect the number of avoided cases but not ICER (Suárez et al., 2008). Current data on Malaysian screening coverage was unavailable, therefore, was largely based on expert opinion. Varying the screening rate in sensitivity analyses did not have a profound effect on results as the changes in outcomes for a given change in screening participation would be similar for both vaccines. We assumed price parity for both vaccines, so that any differences in outcomes were not attributable to vaccine cost, but this is likely not a reality.

Szarewski et al., (2013) recently reported that AS04-HPV-16/18v confers moderate protection against HPV-6/11, further supported by English data demonstrating a marked reduction in GW incidence in a AS04-HPV-16/18v-vaccinated population. They concluded that the patterns of decline by age/gender suggest a moderately protective effect of AS04-HPV-16/18v against GW (Canvin et al., 2016). The current model did not take any efficacy of AS04-HPV-16/18v against GW into account. Had these data been incorporated, results would have been further in favour of AS04-HPV-16/18v.

In conclusion, AS04-HPV-16/18v was predicted to reduce CC cases and deaths in Malaysia, compared with 4vHPVv, due to higher reported rates of protection against non-vaccine HPV types. AS04-HPV-16/18v also resulted in more discounted QALYs gained and lower medical costs. Therefore, UMV with AS04-HPV-16/18v is predicted to dominate in Malaysia when added to the current screening programme, allowing for the reinvestment of saved costs into the needs of the Malaysian population.
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Highlights {#sec2-7}
==========

Effects of HPV vaccination over the lifetime of 259,000 Malaysian girls were modelled.361 less cervical cancer cases are predicted with AS04-HPV-16/18v vs. 4vHPVv.115 less cervical cancer deaths are predicted with AS04-HPV-16/18v vs. 4vHPVv.4,241 fewer cases of genital warts are predicted with 4vHPVv vs. AS04-HPV-16/18v.AS04-HPV-16/18v is predicted to be dominant (246 more QALYs; MYR 18.50 million savings).
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